Start free

Aktis Oncology, Inc. (AKTS) insider trading

Recent insider transactions reported to the SEC on Form 4 — directors and officers buying or selling their own company’s stock. Sourced directly from public SEC filings, latest filed Nov 19, 2026.

Filings shown
9
Open-market buys
2
Open-market sells
11
Buys, 10b5-1 box not checked
2 of 2

Counts cover the 9 most recent Form 4 filings Tradune holds for AKTS (filed Jan 14 – Nov 19, 2026); the score below covers only the trailing 90 days (0 buys, 2 sells). SEC EDGAR Form 4 filings for AKTS last checked Nov 21, 2026, 09:00 UTC; the latest AKTS filing Tradune holds was filed Nov 19, 2026. This is not guaranteed to be the complete record — see AKTS's full Form 4 filing history on SEC EDGAR.

Open-market activity, last 90 days

Purchases (Form 4 code P) and sales (code S) on the 2 filings Tradune holds for AKTS filed Sep 24 – Nov 19, 2026. Grants, exercises, tax withholding and the other Form 4 transaction codes are left out.

2 open-market sales by Rule 10b5-1 checkbox

On filings with the 10b5-1 box checked
2 sales· 12,500 sh
checkbox disclosed
On filings with the box not checked
0 sales· 0 sh
not proof that no plan exists
Not comparable
0 sales· 0 sh
filed before Apr 1, 2023, or no checkbox value in the filing data

Counts are Form 4 lines as filed. The checkbox is one per filing, so every sale on a filing with the box checked is counted there even if only some of its transactions were under a plan; it records what the filer disclosed, and the three categories are not a judgement about why a sale was made.

Open-market purchases and sales by insider
Insider Buys Sells Shares bought Shares sold Value
Akos CzibereChief Medical Officer 0 2 — 12,500 −$258,621

Value = shares × the price reported on each Form 4 (+ purchases, − sales); every open-market line in this window disclosed a price.

Insider-activity score

0/ 100

Net insider sales
0 distinct buyers0 buy · 2 sell tx

Summarises ~90 days of public SEC Form 4 activity — more distinct buyers, officer involvement and net buying score higher. A description of filing activity, not a rating or buy signal. How this score is computed →

Get alerted when insiders buy the stocks you own

Add your holdings — no brokerage login — and Insider Radar sends a Telegram alert when an open-market Form 4 buy of $100,000 or more is filed on a stock you hold or watch.

Free for everyone right now · no card · nothing to buy

Start free

How to read this: an open-market purchase (Form 4 code P) is a buy at the market price with the insider’s own money, as opposed to a grant, award or option exercise; an open-market sale is code S. When two or more distinct insiders report open-market purchases in the same 90-day window, this site labels that a cluster — a definition, not a forecast; see insider cluster buying. “Held after” is Form 4 Table I column 5; “Change” = shares ÷ holdings before the trade (held after − shares for an acquisition, held after + shares for a disposition).

Insider Buying at AKTS

Insiders reported 2 open-market purchases of AKTS between Jan 14, 2026 and Nov 19, 2026, across 2 distinct buyers. The most recent purchase was reported by Ansbert Gadicke (10% owner) on Jan 12, 2026. Grants, option exercises, and tax-withholding transactions are excluded from these counts.

Recent Form 4 filings

Source: SEC EDGAR Form 4 · transaction codes explained

Paul L. Feldman Chief Scientific Officer · filed Nov 19, 2026 · SEC ↗
TransactionSharesPriceHeld afterChange†Date
Option exercise Stock Option (Right to Buy) 55,035 — — — Nov 18, 2026
Option exercise 55,035 $1.90 199,603 +38% Nov 18, 2026

† change in this filer’s own reported holding line (Form 4 Table I, col. 5), not of total company ownership; small prior holdings produce large percentages, so under 100 shares the prior holding is shown instead.

Akos Czibere Chief Medical Officer · filed Sep 24, 2026 · SEC ↗
TransactionSharesPriceHeld afterChange†Date
Option exercise Stock Option (Right to Buy) 12,500 — — — Sep 23, 2026
Open-market sale 10b5-1 box checked 7,401 $21.03 0 −100% Sep 23, 2026
Open-market sale 10b5-1 box checked 5,099 $20.19 7,401 −41% Sep 23, 2026
Option exercise 12,500 $4.95 12,500 — Sep 23, 2026

“10b5-1 box checked” = the filer checked the Form 4 box stating that a transaction on the filing was made under a plan intended to satisfy Rule 10b5-1(c); “10b5-1 box not checked” = the box was left blank, which does not prove that no plan exists. The box applies to Form 4s filed from April 1, 2023; older filings, and boxes we could not read, carry no tag. What the 10b5-1 box means.

Ken Herrmann Director · filed Jul 21, 2026 · SEC ↗
TransactionSharesPriceHeld afterChange†Date
Open-market sale 10b5-1 box not checked 3,506 $24.56 1,350 −72% Jul 20, 2026
Open-market sale 10b5-1 box not checked 1,350 $24.56 0 −100% Jul 20, 2026
Option exercise Stock Option (Right to Buy) 3,506 — — — Jul 20, 2026
Option exercise Stock Option (Right to Buy) 1,350 — — — Jul 20, 2026
Option exercise 3,506 $0.08 3,506 — Jul 20, 2026
Option exercise 1,350 $1.91 4,856 +39% Jul 20, 2026
Ken Herrmann Director · filed Jul 20, 2026 · SEC ↗
TransactionSharesPriceHeld afterChange†Date
Option exercise Stock Option (Right to Buy) 3,065 — — — Jul 17, 2026
Open-market sale 10b5-1 box not checked 3,065 $25.21 0 −100% Jul 17, 2026
Option exercise 3,065 $0.08 3,065 — Jul 17, 2026
Shulamit Ron-Bigger Chief Operating Officer · filed Jul 10, 2026 · SEC ↗
TransactionSharesPriceHeld afterChange†Date
Option exercise 50,000 $3.66 50,000 — Jul 8, 2026
Open-market sale 10b5-1 box not checked 15,800 $27.13 34,200 −32% Jul 8, 2026
Open-market sale 10b5-1 box not checked 4,200 $28.75 0 −100% Jul 8, 2026
Option exercise Stock Option (Right to Buy) 50,000 — — — Jul 8, 2026
Open-market sale 10b5-1 box not checked 30,000 $27.94 4,200 −88% Jul 8, 2026
Akos Czibere Chief Medical Officer · filed Jul 10, 2026 · SEC ↗
TransactionSharesPriceHeld afterChange†Date
Option exercise Stock Option (Right to Buy) 50,000 — — — Jul 8, 2026
Open-market sale 10b5-1 box not checked 14,800 $27.13 35,200 −30% Jul 8, 2026
Option exercise 50,000 $4.95 50,000 — Jul 8, 2026
Open-market sale 10b5-1 box not checked 30,829 $27.95 4,371 −88% Jul 8, 2026
Open-market sale 10b5-1 box not checked 4,371 $28.71 0 −100% Jul 8, 2026
Glenn Gormley Director · filed Apr 16, 2026 · SEC ↗
TransactionSharesPriceHeld afterChange†Date
Grant / award Stock Option (Right to Buy) 37,866 — — — Apr 15, 2026
Todd Foley Director, 10% owner · filed Jan 14, 2026 · SEC ↗
TransactionSharesPriceHeld afterChange†Date
Conversion of derivative Series Seed Redeemable Convertible Preferred Stock 2,272,727 — — — Jan 12, 2026
Conversion of derivative Series B Redeemable Convertible Preferred Stock 2,727,273 — — — Jan 12, 2026
Conversion of derivative Series A Redeemable Convertible Preferred Stock 10,227,273 — — — Jan 12, 2026
Conversion of derivative 2,688,270 — 3,285,661 (indirect) +450% Jan 12, 2026
Open-market purchase 10b5-1 box not checked 232,870 $18.00 4,235,403 (indirect) +5.8% Jan 12, 2026
Conversion of derivative 597,391 — 597,391 (indirect) — Jan 12, 2026
Conversion of derivative 716,872 — 4,002,533 (indirect) +22% Jan 12, 2026
Ansbert Gadicke 10% owner · filed Jan 14, 2026 · SEC ↗
TransactionSharesPriceHeld afterChange†Date
Conversion of derivative 1,314,262 — 1,655,971 (indirect) +385% Jan 12, 2026
Conversion of derivative 5,914,197 — 7,570,168 (indirect) +357% Jan 12, 2026
Conversion of derivative 1,577,119 — 9,147,287 (indirect) +21% Jan 12, 2026
Open-market purchase 10b5-1 box not checked 1,112,777 $18.00 10,260,064 (indirect) +12% Jan 12, 2026
Conversion of derivative Series Seed Redeemable Convertible Preferred Stock 5,000,000 — — — Jan 12, 2026
Conversion of derivative Series A Redeemable Convertible Preferred Stock 22,500,000 — — — Jan 12, 2026
Conversion of derivative Series B Redeemable Convertible Preferred Stock 6,000,000 — — — Jan 12, 2026

Insider filings reported around the same time

Other companies whose most recent Form 4 was filed closest to AKTS's (Nov 19, 2026).

Frequently asked about AKTS insider activity

How many insiders bought AKTS stock in these Form 4 filings?

2 distinct insiders at Aktis Oncology, Inc. reported 2 open-market purchases (Form 4 code P) of AKTS shares between Jan 14, 2026 and Nov 19, 2026, the most recent filed by Ansbert Gadicke (10% owner) on Jan 12, 2026. Grants, option exercises, and tax-withholding transactions are excluded from these counts.

Who filed the most recent Form 4 for AKTS?

The most recent Form 4 on this page was filed by Paul L. Feldman (Chief Scientific Officer) on Nov 19, 2026, reporting 2 transactions. The original document is linked from the filing list above on SEC EDGAR. Amended filings (Form 4/A) may later revise reported figures.

What was the largest open-market AKTS insider purchase shown?

The largest open-market purchase among the filings shown was 1,112,777 AKTS shares at $18.00 (about $20,029,986) by Ansbert Gadicke (10% owner) on Jan 12, 2026. Value is shares × the price reported on the Form 4; its Rule 10b5-1 box is not checked.

Do the recent AKTS insider purchases have the Form 4 10b5-1 box checked?

No. All 2 AKTS open-market purchases shown were reported with the Rule 10b5-1 box not checked. A blank box records what the filer disclosed; it does not prove that no plan exists. Latest: Ansbert Gadicke (10% owner) on Jan 12, 2026, 1,112,777 shares.

New to Form 4s? The transaction codes, the 90-day window and the 0–100 score are defined on the insider-activity score methodology page.

Get insider alerts for AKTS — and your whole portfolio

Tradune watches SEC Form 4 filings and flags insider-cluster buying across everything you hold, routed to you automatically. Free for everyone right now · no card · nothing to buy

This score summarizes SEC Form 4 filing activity over the trailing 90 days. It is descriptive, not predictive — not a rating, recommendation, or investment advice. Data: SEC EDGAR (public domain), as filed; amendments may revise figures. Tradune is not a registered investment adviser.

Data as filed; amended filings (Form 4/A) may revise figures. Sales may occur under prearranged Rule 10b5-1 trading plans.